Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics
CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale
Joseph F. Finn, Jr.,C.P.A. announced that the PRX-07034 Therapeutics - CNS Phase 2 will be part of the intellectual property offered for sale at theSeptember 30, 2009 auction.
The PRX-07034 Therapeutics - CNS Phase 2 is a small molecule, oral 5HT6 antagonist for cognitive impairment associated with schizophrenia (CIAS). The Company has completed Phase 1 in obesity with racemic compound and completed Phase 1 with chiral compound. It has an open IND and a significant quantity of chiral API available.
The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction on September 30, 2009.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.